Key result
Surgical resection of cardiac papillary fibroelastoma is safe, yielding 0% 30-day mortality without valve replacement.
Why the study?
Few institutions have sufficient experience with cardiac papillary fibroelastoma to validate the surgical resection approach, especially for left-sided lesions.
What are the clinical characteristics and surgical outcomes of patients with cardiac papillary fibroelastoma?
Observational (n=14)
No
What are the clinical characteristics and surgical outcomes of patients with cardiac papillary fibroelastoma?
Surgical resection of cardiac papillary fibroelastomas, particularly left-sided lesions, is safe and associated with good postoperative outcomes without the need for valve replacement.
Answers are grounded in this paper and cite their sources.
Supports safe resection of left-sided papillary fibroelastomas in surgical candidates; leaves open management of right-sided or asymptomatic lesions.
In general, treatment for symptomatic and asymptomatic cardiac papillary fibroelastoma is surgical resection-particularly of left-sided lesions, because of the risk of systemic embolization. However, few institutions have enough experience with these tumors to validate this approach. We present our institutional experience with papillary fibroelastoma and discuss our current approach. We searched our institution's cardiac tumor database, identified all patients diagnosed with cardiac papillary fibroelastoma from 1992 through 2014, and recorded the clinical and pathologic characteristics of each case. We found 14 patients (mean age, 60.5 ± 12.3 yr) who had 18 lesions. Eleven patients (79%) were symptomatic; however, we could not always definitively associate their symptoms with a cardiac tumor. Most lesions were solitary and ≤1.5 cm in diameter; half involved the left side of the heart. All 18 lesions were surgically excised. There were no operative or 30-day deaths, and no patient needed valve replacement postoperatively. There was one late death; at one year, another 3 patients were lost to follow-up, and the others were alive without tumor recurrence. Because of the embolic risk inherent to intracardiac masses and our relatively good postoperative outcomes, we recommend the surgical resection of all left-sided papillary fibroelastomas in surgical candidates, and we discuss with patients the advisability of resecting right-sided lesions.
No takes yet. Share an insight, caveat, or question.
Saleh et al. (2016) conducted an observational in Cardiac papillary fibroelastoma (n=14). Surgical resection was evaluated on Operative or 30-day deaths. Surgical resection of cardiac papillary fibroelastoma in 14 patients resulted in 0 operative or 30-day deaths and no need for postoperative valve replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: